Abstracts tagged "osteoarthritis and pain"

Abstract Number: 2182 • 2019 ACR/ARP Annual Meeting
Relation of MRI-detected Structural Damage in the Knee to Anterior Knee Pain: The MOST Study
Joshua Stefanik¹, Tuhina Neogi ², Mohamed Jarraya ³, Ali Guermazi ⁴, Irina Tolstykh ⁵, John Lynch ⁶, James Torner ⁷, Cora Lewis ⁸ and Erin Macri ⁹, ¹Northeastern University, Boston, ²Boston University School of Medicine, Boston, MA, ³Mercy Catholic Medical Center, Darby, ⁴Boston Medical Center, Boston, ⁵UCSF, San Francisco, ⁶University of California at San Francisco, San Francisco, CA, ⁷University of Iowa at Iowa City, Iowa City, ⁸UAB, Birmingham, ⁹Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Discordance between knee osteoarthritis (OA) and knee pain is common yet not well understood. Specifically, anterior knee pain (AKP) is widely held to be…
Abstract Number: 2412 • 2019 ACR/ARP Annual Meeting
Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis
Lavalley Michael¹, Matthew Parkes ², Daniel White ³, Stephan Reichebach ⁴, Timothy McAlindon ⁵ and David Felson ⁶, ¹Boston University, Boston, ²University of Manchester, Manchester, England, United Kingdom, ³University of Delaware, Newark, DE, ⁴University of Bern, Bern, Switzerland, ⁵Tufts Medical Center, Boston, MA, ⁶Boston University School of Medicine, Department of Rheumatology, Boston
Background/Purpose: Minimal important differences (MID), based on within-subject evaluation of attaining an improvement in a continuous outcome such as a pain scale, are important for…
Abstract Number: 2761 • 2019 ACR/ARP Annual Meeting
Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial
Hans Guehring¹, Jeffrey Kraines ², Flavie Moreau ², Benjamin Daelken ¹, Christoph Ladel ¹, Wolfgang Wirth ³, Philip G Conaghan ⁴, Felix Eckstein ⁵ and Marc C. Hochberg ⁶, ¹Merck KGaA, Darmstadt, Germany, ²EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³Paracelsus Medical University, Salzbury, Austria, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Paracelsus Medical University, Salzburg, Austria, ⁶University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Results from the 5-year Phase II FORWARD study showed significant dose-dependent modification of total femorotibial joint (TFTJ) cartilage thickness change with sprifermin at 2…
Abstract Number: 454 • 2018 ACR/ARHP Annual Meeting
Effects of Prolonged Chemogenetic Inhibition of Nociceptors in a Murine Surgical Model of Osteoarthritis
Phuong B. Tran¹, Shingo Ishihara¹, Rachel E. Miller², Richard J. Miller³ and Anne-Marie Malfait⁴, ¹Internal Medicine, Rush University Medical Center, Chicago, IL, ²Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ³Pharmacology/Medical Humanities and Bioethics, Northwestern University, Chicago, IL, ⁴Biochemistry & Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: The aim of this study was to investigate the effects of prolonged chemogenetic inhibition of NaV1.8 nociceptors on pain-related behaviors and cellular changes in…
Abstract Number: 455 • 2018 ACR/ARHP Annual Meeting
Metabolic Syndrome and Trajectories of Pain Severity and Number of Painful Sites in Knee Osteoarthritis: Data from a 10.7-Year Prospective Study
Feng Pan¹, Jing Tian², Flavia Cicuttini³ and Graeme Jones⁴, ¹Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Public health unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ⁴Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Metabolic syndrome (MetS) has been suggested as having a role in osteoarthritis (OA) pathogenesis. No study has assessed whether MetS and its components are…
Abstract Number: 456 • 2018 ACR/ARHP Annual Meeting
Effect of Local and Systemic CCR2 Blockade on Knee Hyperalgesia in a Mouse Model of Osteoarthritis
Shingo Ishihara¹, Rachel E. Miller², Richard J. Miller³ and Anne-Marie Malfait⁴, ¹Internal Medicine, Rush University Medical Center, Chicago, IL, ²Biochemistry, Rush University Medical Center, Chicago, IL, ³Pharmacology/Medical Humanities and Bioethics, Northwestern University, Chicago, IL, ⁴Biochemistry & Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Surgical destabilization of the medial meniscus (DMM) in the mouse knee results in slowly progressive osteoarthritis (OA), characterized by moderate joint damage by week…
Abstract Number: 457 • 2018 ACR/ARHP Annual Meeting
Neuropathic Pain in Patients with Knee Osteoarthritis (Preliminary Report)
Pinar Borman¹, Ferda Kaygisiz² and Aysegul Yaman³, ¹Department of Physical Medicine and Rehabilitation, University of Hacettepe Faculty of Medicine, Ankara, Turkey, ²Dept of PMR, Ankara Training and Research Hospital, Ankara, Turkey, ³Dept of PMR, University of Hacettepe Faculty of Medicine, Ankara, Turkey
Background/Purpose: There are limited studies in the literature indicating that neuropathic pain occurs in knee osteoarthritis (OA) (1). The aim of this cross sectional study…
Abstract Number: 954 • 2018 ACR/ARHP Annual Meeting
A New Way to Think about Composite Magnetic Resonance Imaging Scores to Measure Osteoarthritis Severity and Progression
Lori Lyn Price^1,2, Jeffrey B. Driban³, Grace H. Lo⁴, Ming Zhang⁵, Michael P. LaValley⁶ and Timothy E. McAlindon⁷, ¹Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ²Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, ³Medicine, Division of Rheumatology, Tufts Medical Center, Boston, MA, ⁴Michael E. DeBakey Veterans Affairs Medical Center / Baylor College of Medicine, Houston, TX, ⁵Tufts Medical Center, Boston, MA, ⁶Biostatistics, Boston University School of Public Health, Boston, MA, ⁷Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: For some rheumatologic diseases (e.g. lupus), separate scores evaluate cumulative damage and disease activity. No such strategy exists for osteoarthritis (OA). The prevailing approach…
Abstract Number: 1167 • 2018 ACR/ARHP Annual Meeting
The Role of Fear-Avoidance Model on Pain and Disability in Knee Osteoarthritis Patients
Leticia Leon^1,2, Marta Redondo², Sara Lopez de Felipe², Daniel Garriguez³, Lydia A Alcazar⁴ and Luis Rodriguez-Rodriguez⁵, ¹Rheumatology Department, Hospital Clínical San Carlos, and IdISSC, Madrid, Spain, ²Health Sciences, Universidad Camilo Jose Cela, Madrid, Spain, ³Orthopedics Unit, Hospital Clinico San Carlos, Madrid, Spain, ⁴Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The model of Fear-Avoidance of pain (anxiety, catastrophization and hypervigilance) appears when the pain has maladaptive interpretations, being associated with greater pain and limitations…
Abstract Number: 1169 • 2018 ACR/ARHP Annual Meeting
Association between Depressive Symptom Subtypes and Disease Severity in Knee Osteoarthritis
Alan Rathbun¹, Megan Schuler², Elizabeth Stuart³, Michelle Shardell⁴, Michelle S. Yau⁵, Joseph Gallo⁶ and Marc C. Hochberg⁷, ¹Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, ²Rand Coportation, Boston, MA, ³Mental Health, Biostatistics, and Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, ⁵Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, ⁶Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Latent and modifiable factors, such as depressive symptoms, may affect the course of knee OA. Depression is clinically heterogeneous, and effects on pain and…
Abstract Number: 1170 • 2018 ACR/ARHP Annual Meeting
Sex-Specific Associations between Systemic Inflammatory Cytokines and Osteoarthritis Knee Pain
Anthony V. Perruccio¹, J. Denise Power¹, Mayilee Canizares¹, Elizabeth M. Badley^1,2, Mohit Kapoor¹, Rajiv Gandhi¹ and Y. Raja Rampersaud¹, ¹Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Background/Purpose: Significant challenges remain in mitigating OA pain and despite growing evidence of sex differences, including in pain and in response to NSAIDs, sex has…
Abstract Number: 1364 • 2018 ACR/ARHP Annual Meeting
Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor
Jeyanesh Tambiah¹, Sarah Kennedy¹, Heli Ghandehari¹, Christopher Swearingen¹ and Marc C. Hochberg², ¹Samumed, LLC, San Diego, CA, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, functional limitation, and physical disability due to articular cartilage degradation and bone remodeling. Wnt signaling is involved…
Abstract Number: 1377 • 2018 ACR/ARHP Annual Meeting
Knee Osteoarthritis Symptom Duration Is Associated with Conditioned Pain Modulation and Vibration Perception Threshold Impairment
Kharma C. Foucher¹, Samuel Chmell² and Carol Courtney³, ¹Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, ²Orthopedic Surgery, University of Illinois at Chicago, Chicago, IL, ³Physical Therapy, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Impaired descending pain inhibition has been observed in people with knee OA and may be associated with development of chronic pain as well as…
Abstract Number: 425 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients with Moderate-to-Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study
Naoki Ishiguro¹, Shusuke Oyama², Ryunosuke Higashi³ and Kunio Yanagida⁴, ¹Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Data Science, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ³Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ⁴Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd, Osaka, Japan
Background/Purpose: ONO-4474 is an orally available, peripheral-specific, pan-tropomyosin receptor kinase (pan-Trk) inhibitor currently under development for treatment of musculoskeletal pain in OA patients. This study…
Abstract Number: 1920 • 2018 ACR/ARHP Annual Meeting
Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?
Priyanka Ballal¹, Joachim Scholz², Laura Frey-Law³, Na Wang¹, Michael C. Nevitt⁴, Cora E. Lewis⁵ and Tuhina Neogi⁶, ¹Boston University School of Medicine, Boston, MA, ²Departments of Anesthesiology and Pharmacology, Columbia University Medical Center, New York, NY, ³University of Iowa, Iowa City, IA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Self-reported descriptors of pain in knee osteoarthritis (OA) such as burning and stabbing pain are suggestive of a neuropathic component of pain beyond that…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].